CAM
NVCR icon

Cresset Asset Management’s NovoCure NVCR Stock Holding History

Cresset Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,605
Closed -$1.12M – 2066
2024
Q3 		$1.12M Sell
71,605
-7,583
-10% -$137K ﹤0.01% 1108
2024
Q2 		$1.36M Buy
79,188
+40,139
+103% +$706K 0.01% 906
2024
Q1 		$610K Buy
39,049
+19,010
+95% +$280K ﹤0.01% 1237
2023
Q4 		$299K Buy
+20,039
New +$268K ﹤0.01% 1493

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cresset Asset Management's NVCR Position: Q4 2024 in Review

Cresset Asset Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 71,605 shares — an estimated $1.12M sold.

Cresset Asset Management first reported a position in NVCR in Q4 2023 and held it in 4 quarters. The position peaked at $1.36M in Q2 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Cresset Asset Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 71,605 NovoCure shares in Q4 2024, an estimated $1.12M.
  • Cresset Asset Management first reported a position in NovoCure in Q4 2023 and held it in 4 quarters.
  • Cresset Asset Management's NovoCure position peaked at $1.36M in Q2 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.